Single-dose BNT162b2 vaccine protects against asymptomatic SARS-CoV-2 infection
2021
Nick K Jones | Lucy Rivett | Shaun Seaman | Richard J Samworth | Ben Warne | Chris Workman | Mark Ferris | Jo Wright | Natalie Quinnell | Ashley Shaw | Cambridge COVID-19 Collaboration | Ian G Goodfellow | Paul J Lehner | Rob Howes | Giles Wright | Nicholas J Matheson | Michael P Weekes
The BNT162b2 mRNA COVID-19 vaccine (Pfizer-BioNTech) is being utilised internationally for mass COVID-19 vaccination. Evidence of single-dose protection against symptomatic disease has encouraged some countries to opt for delayed booster doses of BNT162b2, but the effect of this strategy on rates of asymptomatic SARS-CoV-2 infection remains unknown. We previously demonstrated frequent pauci- and asymptomatic SARS-CoV-2 infection amongst healthcare workers (HCWs) during the UK’s first wave of the COVID-19 pandemic, using a comprehensive PCR-based HCW screening programme (Rivett et al., 2020; Jones et al., 2020). Here, we evaluate the effect of first-dose BNT162b2 vaccination on test positivity rates and find a fourfold reduction in asymptomatic infection amongst HCWs ≥12 days post-vaccination. These data provide real-world evidence of short-term protection against asymptomatic SARS-CoV-2 infection following a single dose of BNT162b2 vaccine, suggesting that mass first-dose vaccination will reduce SARS-CoV-2 transmission, as well as the burden of COVID-19 disease.
显示更多 [+] 显示较少 [-]